Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma

NCT03269669 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03269669
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03269669 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 23, 2018
Completion date
January 21, 2027
Enrollment
73 (actual)
Sites
429

Conditions

As the registry lists them; a condition with its own page is linked.

grade 1 follicular lymphoma, grade 2 follicular lymphoma, grade 3a follicular lymphoma, recurrent follicular lymphoma, refractory follicular lymphoma